Vaxart, South San Francisco, California, USA.
Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA.
J Infect Dis. 2022 Jan 5;225(1):34-41. doi: 10.1093/infdis/jiab561.
Vaccines that are shelf stable and easy to administer are crucial to improve vaccine access and reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world.
In this study, we demonstrate that an oral, adenovirus-based vaccine candidate protects against SARS-CoV-2 in a Syrian hamster challenge model.
Hamsters administered 2 doses of VXA-CoV2-1 showed a reduction in weight loss and lung pathology and had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced antispike immunoglobulin G, and neutralizing antibodies were induced upon oral immunization with the sera, demonstrating neutralizing activity.
Overall, these data demonstrate the ability of oral vaccine candidate VXA-CoV2-1 to provide protection against SARS-CoV-2 disease.
易于储存和管理的疫苗对于改善疫苗的可及性和减少全球范围内严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的传播至关重要。
在这项研究中，我们证明了一种基于腺病毒的口服疫苗候选物可在叙利亚仓鼠挑战模型中预防 SARS-CoV-2。
接受 2 剂 VXA-CoV2-1 治疗的仓鼠体重减轻和肺部病理学减少，并且在挑战后 5 天完全消除了传染性病毒。口服免疫可诱导抗刺突免疫球蛋白 G，并且用血清进行口服免疫可诱导中和抗体，显示出中和活性。
总体而言，这些数据表明口服疫苗候选物 VXA-CoV2-1 有能力预防 SARS-CoV-2 疾病。
